Get notified when IVVD files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsStanding Risk Factors
- Going Concern (unchanged) — The auditor's report includes a going-concern explanatory paragraph, indicating substantial doubt about the company's ability to continue operating.
Invivyd files preliminary prospectus for Nasdaq offering; size and price not yet set, last sale $2.35
Filed November 17, 2025 · ~1 min read
Key Changes
-
high
Offering size and price are not yet determined; the prospectus supplement leaves share counts blank pending pricing.
The Offering verify on EDGAR → -
high
Net proceeds to the company are $72.7 million, but this figure is from prior ATM sales, not the current offering.
Use of Proceeds verify on EDGAR → -
high
Proceeds will fund VYD2311 launch preparation, RSV/measles R&D, Long COVID studies, and general corporate purposes.
Use of Proceeds verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
Partner
Trade IVVD commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify